A bispecific EGFR &#215; HER3 antibody-drug conjugate for later-line recurrent or metastatic nasopharyngeal carcinoma: insights from BL-B01D1-303.

izalontamab brengitecan (BL-B01D1) - Sichuan Biokin Pharmaceutical, BMS, Systimmune

A bispecific EGFR × HER3 antibody-drug conjugate for later-line recurrent or metastatic nasopharyngeal carcinoma: insights from BL-B01D1-303. (PubMed, Cancer Biol Med) - Sep 30, 2026 - No abstract available
Journal • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

http://www.ncbi.nlm.nih.gov/pubmed/42806904

Huaqiang Zhou; Jiaqing Liu; Jiayi Shen; Li Zhang; Yunpeng Yang

Sep 30, 2026